瑞迈特 Stock: price and insider trades · China
瑞迈特: what insiders have been doing
This page follows insider dealings at 瑞迈特 as filed with SSE / SZSE (CSRC), a company from the Health Care sector. Between 5 November 2025 and 5 November 2026, 1 insider published 5 filings.
All open-market trades in the period are sales: 5 sales worth €5.5M, by 1 insider, with no purchase on record. The largest single trade was a sale of €5.3M by 陈蓓, published on 5 January 2026.
Most trades are made public on the day they happen. The shorter that gap, the sooner other investors can see what insiders have done. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (521 companies, median 2 filings), a count of 5 filings is above the norm. Our records for 瑞迈特 go back to 2025, with no purchases and 5 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 446,900 shares95.8% of flowA股XSHESZSE:273000000090032100
- 400 shares0.1% of flowA股XSHESZSE:273000000042882100
- 19,200 shares3.6% of flowA股XSHESZSE:273000000037892160
- 1,700 shares0.3% of flowA股XSHESZSE:273000000013333100
- 900 shares0.2% of flowA股XSHESZSE:273000000009180600
5 of 5 declarations
About 瑞迈特
瑞迈特 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the development and commercialization of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
